Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors


EU approves Aquipta for prophylaxis of migraine – AbbVie

Written by | 23 Aug 2023

AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.

Positive CHMP opinion for atogepant for the preventive treatment of adults with migraine – AbbVie

Written by | 29 Jun 2023

AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the… read more.

First-of-its-kind head-to-head clinical trial reaffirms the efficacy of Emgality in episodic migraine prevention – Eli Lilly

Written by | 20 Jun 2023

Eli Lilly and Company announced results of the CHALLENGE-MIG clinical trial of Emgality (galcanezumab-gnlm) and Nurtec ODT (rimegepant orally disintegrating tablet), the first and only trial of its… read more.

FDA approves Qulipta for prevention of migraine – AbbVie

Written by | 19 Oct 2021

The FDA has approved Qulipta (atogepant tablets), from AbbVie, for the preventive treatment of episodic migraine in adults. The approval of Qulipta was based on findings from the… read more.

BioDelivery Sciences International completes acquisition of Elyxyb for acute migraine treatment in the U.S. and Canada

Written by | 26 Sep 2021

BioDelivery Sciences International, Inc. a growing specialty pharmaceutical company dedicated to patients living with chronic conditions, announced that it has completed the acquisition of U.S. and Canadian rights… read more.

FDA approves Trudhesa nasal spray for the treatment of acute migraine – Impel Neuropharma

Written by | 9 Sep 2021

Impel NeuroPharma, Inc. announced that the FDA approved Trudhesa (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) for the acute treatment of migraine with or without aura in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.


You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.